IRADIMED CORP IRMD
IRADIMED CORPORATION ("IRadimed", the "Company," "we," "us," "our" or similar terms) develops, manufactures, markets and distributes Magnetic Resonance Imaging ("MRI") compatible medical devices and related accessories, disposables and services relating to them. We were originally incorporated in Oklahoma under the name IRI Development, Inc. in 1992, and we merged our Oklahoma corporation into the newly formed Delaware corporation, IRADIMED CORPORATION, in April 2014.
We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium 3870 MRI Compatible IV Infusion Pump System, introduced in 2025, has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, touch screen user interface, and other special features to safely and predictably deliver anesthesia and other critical care IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | $41.8M | $31.7M | $38.5M | $30.4M | $23.1M | $32.5M |
| Cost of revenue | $19.5M | $16.9M | $15.4M | $12.0M | $9.8M | $8.1M | $8.8M | $7.2M | $5.6M | $6.2M |
| Gross profit | $64.3M | $56.4M | $50.2M | $41.3M | $32.0M | $23.6M | $29.7M | $23.2M | $17.5M | $26.3M |
| R&D | $3.0M | $2.8M | $2.9M | $2.3M | $1.9M | $1.9M | $1.4M | $1.5M | $1.7M | $1.3M |
| SG&A | $17.8M | $15.9M | $15.1M | $10.7M | $9.8M | $12.3M | $10.5M | $8.7M | $9.0M | $8.8M |
| Total operating expenses | $38.2M | $34.4M | $30.1M | $25.7M | $22.2M | $24.3M | $21.1M | $17.2M | $16.2M | $15.4M |
| Operating income | $26.1M | $22.0M | $20.0M | $15.6M | $9.8M | -$756.1K | $8.6M | $6.0M | $1.3M | $10.9M |
| Pre-tax income | $28.4M | $24.3M | $21.7M | $16.2M | $9.8M | -$616.9K | $9.0M | $6.2M | $1.4M | $11.0M |
| Income tax | $5.9M | $5.0M | $4.5M | $3.4M | $510.8K | $2.0M | $587.6K | $106.1K | $896.6K | $3.7M |
| Net income | $22.5M | $19.2M | $17.2M | $12.8M | $9.3M | $1.4M | $9.6M | $6.3M | $499.8K | $7.2M |
| EPS, basic | 1.77 | 1.52 | 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.59 | 0.05 | 0.67 |
| EPS, diluted | 1.75 | 1.50 | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.60 |
| Shares, diluted (wtd. avg.) | $12.9M | $12.8M | $12.7M | $12.6M | $12.6M | $12.4M | $12.3M | $12.1M | $11.7M | $12.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $51.2M | $52.2M | $49.8M | $58.0M | $62.0M | $50.1M | $43.5M | $28.0M | $18.2M | $17.7M |
| Receivables | $13.7M | $10.6M | $12.2M | $13.3M | $5.1M | $4.6M | $7.3M | $4.2M | $3.8M | $3.8M |
| Inventory | $11.6M | $10.4M | $12.8M | $5.4M | $4.3M | $3.9M | $3.6M | $4.1M | $4.2M | $3.9M |
| Total current assets | $81.2M | $75.2M | $76.0M | $77.5M | $76.2M | $63.7M | $59.0M | $44.5M | $35.1M | $33.9M |
| Property, plant and equipment | $23.9M | $16.8M | $9.3M | $2.4M | $2.1M | $2.1M | $2.1M | $1.9M | $1.9M | $1.5M |
| Other intangibles | $3.4M | $3.1M | $2.5M | $2.1M | $1.1M | $960.9K | $860.1K | $832.5K | $885.5K | $918.7K |
| Total assets | $108.8M | $98.3M | $92.2M | $85.5M | $82.9M | $71.1M | $66.7M | $48.4M | $39.0M | $37.2M |
| Accounts payable | $1.8M | $1.9M | $1.9M | $1.8M | $782.9K | $657.1K | $993.7K | $772.5K | $656.7K | $1.1M |
| Total current liabilities | $10.2M | $8.5M | $16.3M | $8.6M | $6.8M | $4.9M | $5.9M | $4.7M | $4.1M | $3.7M |
| Total liabilities | $14.2M | $11.5M | $20.7M | $11.8M | $10.7M | $9.7M | $11.2M | $6.5M | $6.1M | $5.3M |
| Retained earnings | $64.2M | $56.8M | $43.3M | $47.3M | $47.0M | $37.7M | $36.3M | $26.7M | $20.4M | $19.9M |
| Total equity | $94.6M | $86.8M | $71.4M | $73.7M | $72.2M | $61.4M | $55.5M | $41.9M | $32.9M | $31.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.9M | $25.6M | $13.5M | $10.0M | $11.3M | $5.8M | $10.2M | $7.4M | $3.4M | $9.4M |
| Depreciation and amortisation | $1.2M | $818.0K | $765.2K | $670.7K | $1.4M | $1.3M | $1.2M | $1.1M | $1.3M | $955.8K |
| Stock-based compensation | $2.9M | $2.5M | $2.2M | $1.4M | $1.5M | $4.0M | $1.9M | $1.8M | $2.5M | $1.8M |
| Capital expenditure | $7.8M | $8.0M | $7.4M | $823.0K | $482.3K | $443.0K | $368.3K | $228.3K | $775.6K | $780.8K |
| Investing cash flow | -$8.4M | -$8.8M | -$8.0M | -$1.4M | $648.2K | $247.0K | $3.2M | $1.5M | -$1.0M | -$1.9M |
| Financing cash flow | -$17.6M | -$14.3M | -$13.7M | -$12.7M | $24.4K | $522.5K | $2.0M | $929.9K | -$1.9M | -$9.1M |
| Dividends paid | $15.0M | $13.7M | $13.2M | $12.6M | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | $1.8M | $10.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028903.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |